# Gentherm Inc: financial statements, quarterly

THRM · Nasdaq · CIK 903129 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/thrm.md) · [Financials](/companies/thrm/financials.md) · [Filings](/companies/thrm/filings.md) · [Insiders](/companies/thrm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/thrm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [367 d](/filings/0001193125-26-059602.md) | [356](/filings/0000950170-25-057994.md) | [376](/filings/0000950170-25-098386.md) | [372](/filings/0001193125-25-248864.md) | [353 d](/filings/0001193125-26-059602.md) | [354](/filings/0001193125-26-173920.md) | [375](/filings/0001193125-26-314184.md) | [387](/filings/0001193125-26-428998.md) | [383 d](/filings/0001193125-26-059602.md) | [394](/filings/0001193125-26-173920.md) | [416](/filings/0001193125-26-314184.md) | [405](/filings/0001193125-26-428998.md) |
| Cost of revenue | $m | [271 d](/filings/0001193125-26-059602.md) | [267](/filings/0000950170-25-057994.md) | [279](/filings/0000950170-25-098386.md) | [277](/filings/0001193125-25-248864.md) | [267 d](/filings/0001193125-26-059602.md) | [267](/filings/0001193125-26-173920.md) | [285](/filings/0001193125-26-314184.md) | [292](/filings/0001193125-26-428998.md) | [292 d](/filings/0001193125-26-059602.md) | [296](/filings/0001193125-26-173920.md) | [320](/filings/0001193125-26-314184.md) | [311](/filings/0001193125-26-428998.md) |
| Gross profit | $m | [96.3 d](/filings/0001193125-26-059602.md) | [88.8](/filings/0000950170-25-057994.md) | [96.7](/filings/0000950170-25-098386.md) | [94.9](/filings/0001193125-25-248864.md) | [86.1 d](/filings/0001193125-26-059602.md) | [86.5](/filings/0001193125-26-173920.md) | [89.8](/filings/0001193125-26-314184.md) | [95.1](/filings/0001193125-26-428998.md) | [90.8 d](/filings/0001193125-26-059602.md) | [97.2](/filings/0001193125-26-173920.md) | [96.4](/filings/0001193125-26-314184.md) | [94.3](/filings/0001193125-26-428998.md) |
| Research and development | $m | [21.4 d](/filings/0001193125-26-059602.md) | [22.7](/filings/0000950170-25-057994.md) | [21.9](/filings/0000950170-25-098386.md) | [23.0](/filings/0001193125-25-248864.md) | [21.1 d](/filings/0001193125-26-059602.md) | [24.2](/filings/0001193125-26-173920.md) | [22.6](/filings/0001193125-26-314184.md) | [24.4](/filings/0001193125-26-428998.md) | [23.6 d](/filings/0001193125-26-059602.md) | [23.9](/filings/0001193125-26-173920.md) | [24.1](/filings/0001193125-26-314184.md) | [23.5](/filings/0001193125-26-428998.md) |
| Selling, general and administrative | $m | [41.9 d](/filings/0001193125-26-059602.md) | [40.7](/filings/0000950170-25-057994.md) | [39.4](/filings/0000950170-25-098386.md) | [36.9](/filings/0001193125-25-248864.md) | [38.1 d](/filings/0001193125-26-059602.md) | [38.5](/filings/0001193125-26-173920.md) | [41.1](/filings/0001193125-26-314184.md) | [42.9](/filings/0001193125-26-428998.md) | [47.6 d](/filings/0001193125-26-059602.md) | [55.3](/filings/0001193125-26-173920.md) | [55.7](/filings/0001193125-26-314184.md) | [51.6](/filings/0001193125-26-428998.md) |
| Operating income | $m | [31.7 d](/filings/0001193125-26-059602.md) | [18.0](/filings/0000950170-25-057994.md) | [33.0](/filings/0000950170-25-098386.md) | [32.3](/filings/0001193125-25-248864.md) | [23.6 d](/filings/0001193125-26-059602.md) | [17.1](/filings/0001193125-26-173920.md) | [24.0](/filings/0001193125-26-314184.md) | [23.9](/filings/0001193125-26-428998.md) | [17.8 d](/filings/0001193125-26-059602.md) | [11.3](/filings/0001193125-26-173920.md) | [10.7](/filings/0001193125-26-314184.md) | [14.4](/filings/0001193125-26-428998.md) |
| Income tax | $m | [(0.9) d](/filings/0001193125-26-059602.md) | [3.5](/filings/0000950170-25-057994.md) | [9.5](/filings/0000950170-25-098386.md) | [3.4](/filings/0001193125-25-248864.md) | [20.8 d](/filings/0001193125-26-059602.md) | [2.2](/filings/0001193125-26-173920.md) | [2.1](/filings/0001193125-26-314184.md) | [5.9](/filings/0001193125-26-428998.md) | [7.3 d](/filings/0001193125-26-059602.md) | [3.4](/filings/0001193125-26-173920.md) | [2.9](/filings/0001193125-26-314184.md) | [13.4](/filings/0001193125-26-428998.md) |
| Net income | $m | [18.1 d](/filings/0001193125-26-059602.md) | [14.8](/filings/0001193125-25-248864.md) | [18.9](/filings/0001193125-25-248864.md) | [16.0](/filings/0001193125-25-248864.md) | [15.3 d](/filings/0001193125-26-059602.md) | [(0.1)](/filings/0001193125-26-428998.md) | [0.5](/filings/0001193125-26-428998.md) | [14.9](/filings/0001193125-26-428998.md) | [3.0 d](/filings/0001193125-26-059602.md) | [4.2](/filings/0001193125-26-428998.md) | [4.4](/filings/0001193125-26-428998.md) | [(2.6)](/filings/0001193125-26-428998.md) |
| Diluted EPS | $ per share | not reported | [0.47](/filings/0000950170-25-057994.md) | [0.60](/filings/0000950170-25-098386.md) | [0.51](/filings/0001193125-25-248864.md) | not reported | [0.00](/filings/0001193125-26-173920.md) | [0.02](/filings/0001193125-26-314184.md) | [0.49](/filings/0001193125-26-428998.md) | not reported | [0.14](/filings/0001193125-26-173920.md) | [0.14](/filings/0001193125-26-314184.md) | [(0.08)](/filings/0001193125-26-428998.md) |
| Basic EPS | $ per share | not reported | [0.47](/filings/0000950170-25-057994.md) | [0.60](/filings/0000950170-25-098386.md) | [0.51](/filings/0001193125-25-248864.md) | not reported | [0.00](/filings/0001193125-26-173920.md) | [0.02](/filings/0001193125-26-314184.md) | [0.49](/filings/0001193125-26-428998.md) | not reported | [0.14](/filings/0001193125-26-173920.md) | [0.14](/filings/0001193125-26-314184.md) | [(0.08)](/filings/0001193125-26-428998.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [150](/filings/0000950170-25-023344.md) | [125](/filings/0000950170-24-050570.md) | [123](/filings/0000950170-24-088484.md) | [151](/filings/0000950170-24-119052.md) | [134](/filings/0001193125-26-059602.md) | [163](/filings/0000950170-25-057994.md) | [128](/filings/0000950170-25-098386.md) | [154](/filings/0001193125-25-248864.md) | [161](/filings/0001193125-26-428998.md) | [177](/filings/0001193125-26-173920.md) | [213](/filings/0001193125-26-314184.md) | [252](/filings/0001193125-26-428998.md) |
| Current assets | $m | [688](/filings/0000950170-25-023344.md) | [700](/filings/0000950170-24-050570.md) | [690](/filings/0000950170-24-088484.md) | [737](/filings/0000950170-24-119052.md) | [684](/filings/0001193125-26-059602.md) | [764](/filings/0000950170-25-057994.md) | [759](/filings/0000950170-25-098386.md) | [786](/filings/0001193125-25-248864.md) | [777](/filings/0001193125-26-428998.md) | [826](/filings/0001193125-26-173920.md) | [880](/filings/0001193125-26-314184.md) | [927](/filings/0001193125-26-428998.md) |
| Total assets | $m | [1,234](/filings/0000950170-25-023344.md) | [1,253](/filings/0000950170-24-050570.md) | [1,241](/filings/0000950170-24-088484.md) | [1,298](/filings/0000950170-24-119052.md) | [1,248](/filings/0001193125-26-059602.md) | [1,344](/filings/0000950170-25-057994.md) | [1,361](/filings/0000950170-25-098386.md) | [1,381](/filings/0001193125-25-248864.md) | [1,396](/filings/0001193125-26-428998.md) | [1,430](/filings/0001193125-26-173920.md) | [1,493](/filings/0001193125-26-314184.md) | [1,562](/filings/0001193125-26-428998.md) |
| Current liabilities | $m | [325](/filings/0000950170-25-023344.md) | [333](/filings/0000950170-24-050570.md) | [326](/filings/0000950170-24-088484.md) | [365](/filings/0000950170-24-119052.md) | [340](/filings/0001193125-26-059602.md) | [353](/filings/0000950170-25-057994.md) | [377](/filings/0000950170-25-098386.md) | [400](/filings/0001193125-25-248864.md) | [404](/filings/0001193125-26-428998.md) | [418](/filings/0001193125-26-173920.md) | [426](/filings/0001193125-26-314184.md) | [452](/filings/0001193125-26-428998.md) |
| Total liabilities | $m | [590](/filings/0000950170-25-023344.md) | [606](/filings/0000950170-24-050570.md) | [600](/filings/0000950170-24-088484.md) | [637](/filings/0000950170-24-119052.md) | [631](/filings/0001193125-26-059602.md) | [698](/filings/0000950170-25-057994.md) | [662](/filings/0000950170-25-098386.md) | [663](/filings/0001193125-25-248864.md) | [676](/filings/0001193125-26-428998.md) | [714](/filings/0001193125-26-173920.md) | [770](/filings/0001193125-26-314184.md) | [841](/filings/0001193125-26-428998.md) |
| Long-term debt | $m | [222](/filings/0000950170-25-023344.md) | [222](/filings/0000950170-24-050570.md) | [222](/filings/0000950170-24-088484.md) | [222](/filings/0000950170-24-119052.md) | [220](/filings/0001193125-26-059602.md) | [262](/filings/0000950170-25-057994.md) | [209](/filings/0000950170-25-098386.md) | [189](/filings/0001193125-25-248864.md) | [189](/filings/0001193125-26-428998.md) | [219](/filings/0001193125-26-173920.md) | [272](/filings/0001193125-26-314184.md) | [320](/filings/0001193125-26-428998.md) |
| Current portion of debt | $m | [0.6](/filings/0000950170-25-023344.md) | [0.3](/filings/0000950170-24-050570.md) | [0.3](/filings/0000950170-24-088484.md) | [0.2](/filings/0000950170-24-119052.md) | [0.1](/filings/0001193125-26-059602.md) | [0.1](/filings/0000950170-25-057994.md) | [0.1](/filings/0000950170-25-098386.md) | [0.1](/filings/0001193125-25-248864.md) | [0.1](/filings/0001193125-26-428998.md) | [0.0](/filings/0001193125-26-173920.md) | [0.9](/filings/0001193125-26-314184.md) | [0.9](/filings/0001193125-26-428998.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [645](/filings/0001193125-26-059602.md) | [647](/filings/0001193125-25-248864.md) | [640](/filings/0001193125-25-248864.md) | [661](/filings/0001193125-25-248864.md) | [617](/filings/0001193125-26-428998.md) | [647](/filings/0001193125-26-428998.md) | [700](/filings/0001193125-26-428998.md) | [718](/filings/0001193125-26-428998.md) | [720](/filings/0001193125-26-428998.md) | [716](/filings/0001193125-26-428998.md) | [723](/filings/0001193125-26-428998.md) | [721](/filings/0001193125-26-428998.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [39.2 d](/filings/0001193125-26-059602.md) | [(10.3)](/filings/0000950170-25-057994.md) | [37.1 d](/filings/0000950170-25-098386.md) | [46.3 d](/filings/0001193125-25-248864.md) | [36.6 d](/filings/0001193125-26-059602.md) | [(13.3)](/filings/0001193125-26-173920.md) | [45.0 d](/filings/0001193125-26-314184.md) | [56.1 d](/filings/0001193125-26-428998.md) | [29.0 d](/filings/0001193125-26-059602.md) | [(5.0)](/filings/0001193125-26-173920.md) | [7.3 d](/filings/0001193125-26-314184.md) | [33.7 d](/filings/0001193125-26-428998.md) |
| Capital expenditure | $m | [11.1 d](/filings/0001193125-26-059602.md) | [11.3](/filings/0000950170-25-057994.md) | [19.4 d](/filings/0000950170-25-098386.md) | [19.7 d](/filings/0001193125-25-248864.md) | [23.0 d](/filings/0001193125-26-059602.md) | [14.9](/filings/0001193125-26-173920.md) | [8.9 d](/filings/0001193125-26-314184.md) | [9.7 d](/filings/0001193125-26-428998.md) | [22.3 d](/filings/0001193125-26-059602.md) | [5.7](/filings/0001193125-26-173920.md) | [8.6 d](/filings/0001193125-26-314184.md) | [8.4 d](/filings/0001193125-26-428998.md) |
| Share repurchases | $m | [60.0 d](/filings/0001193125-26-059602.md) | [0.0](/filings/0000950170-25-057994.md) | [21.7 d](/filings/0000950170-25-098386.md) | [19.9 d](/filings/0001193125-25-248864.md) | [10.0 d](/filings/0001193125-26-059602.md) | [0.0](/filings/0000950170-25-057994.md) | [10.0 d](/filings/0001193125-26-314184.md) | [0.0 d](/filings/0001193125-26-428998.md) | [0.0 d](/filings/0001193125-26-059602.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.4](/filings/0000950170-24-050570.md) | [33.0](/filings/0000950170-24-088484.md) | [33.2](/filings/0000950170-24-119052.md) | [31.7](/filings/0000950170-25-057994.md) | [31.7](/filings/0000950170-25-098386.md) | [31.4](/filings/0001193125-25-248864.md) | [30.8](/filings/0001193125-26-173920.md) | [30.7](/filings/0001193125-26-314184.md) | [30.7](/filings/0001193125-26-428998.md) | [30.8](/filings/0001193125-26-173920.md) | [31.1](/filings/0001193125-26-314184.md) | [30.7](/filings/0001193125-26-428998.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 52,504,512 at 2026-10-16, from the cover of the [10-Q filed 2026-10-22](/filings/0001193125-26-428998.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.